The data presented in this article are related to the research article entitled “Acute Hospital Administration of Amiodarone and/or Lidocaine in Shockable Patients Presenting with Out-of-hospital Cardiac Arrest: A Nationwide Cohort Study” (C.H. Huang, P.H. Yu, M.S. Tsai et al., 2016) [1]. The data contains the information of co-morbidities coding from ICD-9 CM codes and specific difference in requirement between medical centers and non-medical centers in resuscitation. Univariate and multivariate logistic regression analysis for factors related to the outcome of survival to ICU admission and survival to hospital discharge are included in the data set. The data also contains bootstrap sensitivity analysis of the logistic regression model for survival to ICU admission and hospital discharge outcomes in out-of-hospital cardiac arrest. Subgroup analysis of epinephrine dosage related to outcome of one-year survival is shown.

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

DOI of original article: http://dx.doi.org/10.1016/j.ijcard.2016.11.101
* Corresponding author.
E-mail address: wjchen1955@ntu.edu.tw (W.-J. Chen).

Data Article

Data for outcomes of acute hospital administration of amiodarone and/or lidocaine in shockable patients presenting with out-of-hospital cardiac arrest

Chien-Hua Huang, Ping-Hsun Yu, Min-Shan Tsai, Po-Ya Chuang, Tzung-Dau Wang, Chih-Yen Chiang, Wei-Tien Chang, Matthew Huei-Ming Ma, Chao-Hsiun Tang, Wen-Jone Chen*

Department of Emergency Medicine and Department of Internal Medicine (Cardiology), College of Medicine, National Taiwan University, Taipei, Taiwan
Specifications Table

| Subject area       | Biology                           |
|--------------------|----------------------------------|
| More specific sub- | Acute cardiac care               |
| ject area           |                                  |
| Type of data       | Tables                           |
| How data was       | Data analysis for national health insurance database |
| acquired           |                                  |
| Data format        | Analyzed                         |
| Experimental factors | Data are analyzed to figure out the outcomes related variables |
| features           | Retrospective, observational, and nationwide population-based cohort study of patients with non-traumatic cardiac arrest |
| Data source location | A nationwide cohort study in Taiwan |
| Data accessibility | The analyzed data is with this article. |

Value of the data

- The data provide information the ways of coding co-morbidities and hospital levels in the resuscitation study. The short term outcomes of survival to hospital admission, intermediate outcome of survival to hospital discharge are important in cardiac arrest patient.
- The data provides the information so that the effects of specific intervention can be comprehensively figured out and compared.
- Subgroup analysis of patients with different dosage of epinephrine used in resuscitation show the interaction with effects of anti-arrhythmic agents.

1. Data

The data contains the information of co-morbidities coding from ICD-9 CM codes and specific difference in requirement between medical centers and non-medical centers in resuscitation as shown in Tables 1 and 2. Univariate and multivariate logistic regression analysis for factors related to the outcome of survival to ICU admission and survival to hospital discharge are included in the data set Tables 3a and 3b. The data also contains bootstrap sensitivity analysis of the logistic regression model for survival to ICU admission and hospital discharge outcomes in out-of-hospital cardiac arrest as shown in Table 4. Subgroup analysis of epinephrine dosage related to outcome of one-year survival is shown in Table 5.

Table 1

Co-morbidities coding from ICD-9 CM codes.

| Co-morbidities                     | ICD-9 CM codes |
|------------------------------------|----------------|
| Diabetes mellitus                  | 250.*          |
| Hypertension                       | 401.*, 402.*, 403.*, 404.*, 405.* |
| Coronary artery disease            | 410.*, 411.*, 412.*, 413.*, 414.* |
| Congestive heart failure           | 428.*          |
| Atrial fibrillation                | 42731          |
| Chronic kidney disease             | 585            |
| Malignancy                         | 140.* – 172.*, 174.* ~ 194*, 200.* ~ 208.* |
| Chronic obstructive pulmonary disease | 491.*, 492.*, 494.*, 496.* |
| Asthma                             | 493.*          |
Table 2
Specific difference in requirement between medical centers and non-medical centers in resuscitation.

|                         | Medical centre | Non-medical centre |
|-------------------------|----------------|-------------------|
| Chief of emergency      | Emergency medicine specialist | Any medical specialist |
| Physician qualification | 1. 70% of total physicians are fixed in ED | 1. 30% of total physicians are fixed in ED |
|                         | 2. More than 50% of total fixed physician are emergency medicine specialist | 2. Any medical specialist |
| Qualified advanced      | More than 75% of total stuff (including physicians and nurses) | More than 50% of total stuff (including physicians and nurses) |
| cardiac life support    | Cardiologist and cardiovascular surgeon consultation at any time | Cardiologist consultation at any time |
| (ACLS) training         | Management for acute coronary syndrome | Management for acute coronary syndrome |
| Perform percutaneous    | 1. Always available at any time | 1. Not always available |
| coronary intervention   | 2. Door-to-balloon time < 90 min in 75% of total STEMI patients | 2. Transfer the patient if PCI is not available |

Table 3a
Univariate and multivariate logistic regression analysis for factors related to the outcome of survival to ICU admission.

|                         | Univariate | Multivariate |
|-------------------------|------------|--------------|
|                         | OR (95% CI) | P value | OR (95% CI) | P value |
| Age (pear year)         | 0.99(0.99 ~ 0.99) | < 0.0001 | 0.99 (0.98 ~ 0.99) | < 0.0001 |
| Male                    | 0.92(0.87 ~ 0.98) | 0.0141 | 0.91 (0.85 ~ 0.98) | 0.01 |
| Medication use          |            |            |            |            |
| Both                    | 2.82(2.52 ~ 3.17) | < 0.0001 | 4.05(3.56 ~ 4.61) | < 0.0001 |
| Amiodarone              | 2.04(1.90 ~ 2.18) | < 0.0001 | 2.23(2.07 ~ 2.41) | < 0.0001 |
| Lidocaine               | 1.87(1.62 ~ 2.16) | < 0.0001 | 2.32(1.99 ~ 2.71) | < 0.0001 |
| Neither                 | 1           | 1           | 1           | 1           |
| Urbanization level      |            |            |            |            |
| 1                       | 1.35(1.24 ~ 1.47) | 1.23(1.12 ~ 1.36) | < 0.0001 | < 0.0001 |
| 2                       | 1.41(1.30 ~ 1.52) | 1.26(1.16 ~ 1.37) | < 0.0001 | < 0.0001 |
| 3                       | 1.22(1.10 ~ 1.37) | 1.36(1.21 ~ 1.53) | < 0.0001 | < 0.0001 |
| 4                       | 1           | 1           | 1           | 1           |
| CCI                     | 0.98(0.97 ~ 0.99) | < 0.0001 |            |            |
| Pre-existing medical disease<sup>a</sup> |            |            |            |            |
| DM                      | 1.06(0.9956 ~ 1.14) | 0.06 |            |            |
| Hypertension            | 0.93(0.87 ~ 0.98) | 0.01 |            |            |
| CAD                     | 0.88(0.82 ~ 0.95) | 0.0007 | 0.89(0.82 ~ 0.97) | 0.005 |
| HF                      | 0.94(0.86 ~ 1.03) | 0.18 | 1          | 0.88(0.78 ~ 0.98) | 0.02 |
| Af                      | 1.16(0.99 ~ 1.35) | 0.06 | 1.20(1.01 ~ 1.41) | 0.03 |
| CKD                     | 1.16(1.05 ~ 1.28) | 0.0024 |            |            |
| Malignancy              | 0.93(0.83 ~ 1.03) | 0.17 | 1          | 0.88(0.78 ~ 0.98) | 0.02 |
| COPD                    | 0.80(0.73 ~ 0.88) | < 0.0001 |            |            |
| Asthma                  | 0.85(0.75 ~ 0.97) | 0.01 |            |            |
| Year of events          |            |            |            |            |
| 2004                    | 1.17(1.03 ~ 1.33) | 0.01 | 1.19(1.04 ~ 1.35) | 0.01 |
| 2005                    | 1.54(1.37 ~ 1.74) | < 0.0001 | 1.50(1.32 ~ 1.70) | < 0.0001 |
| 2006                    | 1.54(1.36 ~ 1.74) | < 0.0001 | 1.48(1.30 ~ 1.69) | < 0.0001 |
| 2007                    | 1.82(1.61 ~ 2.05) | < 0.0001 | 1.75(1.54 ~ 1.99) | < 0.0001 |
| 2008                    | 1.78(1.57 ~ 2.01) | < 0.0001 | 1.81(1.59 ~ 2.06) | < 0.0001 |
| 2009                    | 1.82(1.61 ~ 2.07) | < 0.0001 | 1.78(1.56 ~ 2.03) | < 0.0001 |
| 2010                    | 1.73(1.52 ~ 1.96) | < 0.0001 | 1.72(1.50 ~ 1.97) | < 0.0001 |
| 2011                    | 1.70(1.58 ~ 1.82) | < 0.0001 | 1.60(1.47 ~ 1.74) | < 0.0001 |
| Epinephrine dose (per mg)| 0.90(0.89 ~ 0.90) | < 0.0001 | 0.87(0.87 ~ 0.88) | < 0.0001 |
| Vasopressin use         | 2.14(0.97 ~ 4.48) | 0.03 | 2.86(1.35 ~ 6.06) | 0.006 |
| Resuscitation in         | 1.70(1.58 ~ 1.82) | < 0.0001 |            |            |
| medical centre          |            |            |            |            |

Regression to age, gender, underlying diseases, Charlson comorbidity index, epinephrine dose, vasopressin use, hospital level, urbanization level, year of event.

OD: odds ratio; CI: confidence interval.

<sup>a</sup> CCI: Charlson comorbidity index; DM: diabetes mellitus; CAD: coronary artery disease; HF: heart failure; Af: atrial fibrillation; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease.
### Table 3b
Univariate and multivariate analysis for factors related to the outcome of survival to hospital discharge.

| Factor                        | Univariate OR (95% CI) | Univariate P value | Multivariate OR (95% CI) | Multivariate P value |
|-------------------------------|------------------------|--------------------|--------------------------|----------------------|
| Age, pear year                | 0.98 (0.98 – 0.98)     | < 0.0001           | 0.99 (0.98 – 0.99)       | < 0.0001             |
| Male                          | 1.16 (1.03 – 1.30)     | 0.01               | 0.99 (0.98 – 0.99)       | < 0.0001             |
| Medication                    |                        |                    |                          |                      |
| Both                          | 4.46 (3.76 – 5.28)     | < 0.0001           | 4.26 (3.36 – 5.41)       | < 0.0001             |
| Amiodarone                    | 3.08 (2.74 – 3.45)     | < 0.0001           | 2.79 (2.40 – 3.24)       | < 0.0001             |
| Lidocaine                     | 2.66 (2.11 – 3.35)     | < 0.0001           | 2.51 (1.88 – 3.36)       | < 0.0001             |
| Neither                       | 1                      |                    |                          |                      |
| Urbanization Level            |                        |                    |                          |                      |
| 1                             | 1.50 (1.29 – 1.73)     | < 0.0001           |                          |                      |
| 2                             | 1.35 (1.18 – 1.55)     | < 0.0001           |                          |                      |
| 3                             | 1.13 (0.93 – 1.38)     | 0.23               |                          |                      |
| 4                             | 1                      |                    |                          |                      |
| CCI                            | 0.88 (0.86 – 0.90)     | < 0.0001           | 0.95 (0.92 – 0.99)       | 0.005                |
| Pre-existing medical disease   |                        |                    |                          |                      |
| DM                            | 0.77 (0.68 – 0.88)     | < 0.0001           |                          |                      |
| Hypertension                  | 0.80 (0.71 – 0.89)     | < 0.0001           |                          |                      |
| CAD                           | 0.81 (0.71 – 0.93)     | 0.0026             |                          |                      |
| heart failure                 | 0.86 (0.73 – 1.00)     | 0.052              |                          |                      |
| Af                            | 0.90 (0.66 – 1.21)     |                    |                          |                      |
| CKD                           | 1.03 (0.86 – 1.23)     | 0.74               | 1.46 (1.16 – 1.84)       | 0.001                |
| Malignancy                    | 0.63 (0.50 – 0.79)     | < 0.0001           |                          |                      |
| CPOD                          | 0.58 (0.49 – 0.69)     | < 0.0001           |                          |                      |
| Asthma                        | 0.76 (0.59 – 0.97)     | 0.03               | 1.45 (1.12 – 1.90)       | 0.006                |
| Year of events                |                        |                    |                          |                      |
| 2004                          | 1                      |                    |                          |                      |
| 2005                          | 1.13 (0.90 – 1.42)     | 0.29               |                          |                      |
| 2006                          | 1.44 (1.16 – 1.79)     | 0.0011             |                          |                      |
| 2007                          | 1.53 (1.23 – 1.91)     | 0.0002             |                          |                      |
| 2008                          | 1.78 (1.44 – 2.21)     | < 0.0001           |                          |                      |
| 2009                          | 1.85 (1.49 – 2.30)     | < 0.0001           |                          |                      |
| 2010                          | 1.86 (1.49 – 2.32)     | < 0.0001           |                          |                      |
| 2011                          | 1.73 (1.38 – 2.17)     | < 0.0001           |                          |                      |
| Epinephrine dose (per mg)     | 0.79 (0.78 – 0.80)     | < 0.0001           | 0.80 (0.79 – 0.81)       | < 0.0001             |
| Vasopressin                   | 1.04 (0.12 – 4.07)     | 0.72               |                          |                      |
| Resuscitation in medical centre | 1.91 (1.70 – 2.14) | < 0.0001           | 1.38 (1.19 – 1.61)       | < 0.0001             |
| Coronary angiography          | 66.71 (56.90 – 78.25)  | < 0.0001           | 32.86 (27.11 – 39.83)    | < 0.0001             |
| Hypothermia                   | 11.28 (9.62 – 18.14)   | < 0.0001           |                          |                      |

Regression to age, gender, underlying diseases, Charlson comorbidity index, epinephrine dose, vasopressin use, hospital level, urbanization level, year of event, coronary angiography.

OD: odds ratio, CI: confidence interval.

a CCI: Charlson comorbidity index; DM: diabetes mellitus; CAD: coronary artery disease; HF: heart failure; Af: atrial fibrillation; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease.
2. Experimental design, materials and methods

Medical records/reports accruing between years 2004 and 2011 were retrieved from the Taiwan National Health Insurance Research Database (NHIRD) for review. This repository releases anonymous secondary data for research purposes and houses all claims data from the National Health Insurance (NHI) program in Taiwan. Launched in 1995, the NHI provides coverage for > 99% of the entire Taiwanese population of 23.74 million [2]. The database details all patient demographics and orders for medical care. Taiwan’s NHI Bureau is responsible for comprehensive review of medical records and examination reports [3]. Disease diagnoses are coded according to the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM). The study protocol was approved by the National Taiwan University Hospital Research Ethics Committee.

### Table 4
Bootstrap sensitivity analysis of the logistic regression model for survival to ICU admission and hospital discharge outcomes in out-of-hospital cardiac arrest.

| Survival to ICU admission | Survival to discharge |
|---------------------------|-----------------------|
|                           | Adjusted OR (95% CI)  | \( P \) value | Adjusted OR (95% CI) | \( P \) value |
| **Primary analysis**      |                       |               |                        |               |
| Both                      | 4.05 (4.04–4.07)      | < 0.0001      | 4.17 (4.14–4.20)       | < 0.0001      |
| Amiodarone                | 2.23 (2.23–2.24)      | < 0.0001      | 2.72 (2.70–2.73)       | < 0.0001      |
| Lidocaine                 | 2.33 (2.32–2.34)      | < 0.0001      | 2.51 (2.48–2.53)       | < 0.0001      |
| Neither                   | Reference             |               | Reference              |               |
| **Excluding patients with pre-existing malignancy** |                   |               |                        |               |
| Both                      | 4.15 (4.13–4.17)      | < 0.0001      | 4.14 (4.11–4.17)       | < 0.0001      |
| Amiodarone                | 2.32 (2.31–2.32)      | < 0.0001      | 2.71 (2.70–2.73)       | < 0.0001      |
| Lidocaine                 | 2.51 (2.50–2.52)      | < 0.0001      | 2.63 (2.60–2.65)       | < 0.0001      |
| Neither                   | Reference             |               | Reference              |               |
| **Excluding patients receiving no epinephrine** |                   |               |                        |               |
| Both                      | 3.97 (3.95–3.99)      | < 0.0001      | 4.42 (4.39–4.46)       | < 0.0001      |
| Amiodarone                | 2.16 (2.16–2.17)      | < 0.0001      | 2.81 (2.80–2.83)       | < 0.0001      |
| Lidocaine                 | 2.19 (2.18–2.20)      | < 0.0001      | 2.41 (2.39–2.44)       | < 0.0001      |
| Neither                   | Reference             |               | Reference              |               |
| **Excluding patients receiving epinephrine 0 or 1 mg** |                   |               |                        |               |
| Both                      | 3.86 (3.85–3.88)      | < 0.0001      | 4.38 (4.34–4.41)       | < 0.0001      |
| Amiodarone                | 2.12 (2.11–2.12)      | < 0.0001      | 2.86 (2.84–2.87)       | < 0.0001      |
| Lidocaine                 | 2.11 (2.10–2.12)      | < 0.0001      | 2.46 (2.43–2.49)       | < 0.0001      |
| Neither                   | Reference             |               | Reference              |               |

OR: odds ratio, CI: confidence interval.

### Table 5
Subgroup analysis of epinephrine dosage related to outcome of one-year survival.

| Epinephrine dosage | Both | Amiodarone | Lidocaine | Neither |
|--------------------|------|------------|-----------|---------|
| \( \leq 5 \) mg     | 2.60 (1.72–3.93) | 2.36 (1.88–2.96) | 2.06 (1.34–3.16) | Reference |
| \( P \) value       | < 0.0001 | < 0.0001 | 0.0009    |         |
| 6–10 mg             | 2.47 (1.54–3.98) | 2.37 (1.79–3.14) | 1.83 (1.01–3.32) | Reference |
| \( P \) value       | 0.0002 | < 0.0001 | 0.047     |         |
| 11–15 mg            | 2.51 (1.45–4.33) | 1.18 (0.78–1.80) | 1.31 (0.56–3.05) | Reference |
| \( P \) value       | 0.001 | 0.43       | 0.54      |         |
| > 15 mg             | 1.46 (0.85–2.51) | 1.33 (0.88–2.02) | 1.18 (0.46–2.98) | Reference |
| \( P \) value       | 0.17  | 0.17       | 0.73      |         |

\( P \) value for interaction < 0.0001.
3. Study design

This retrospective, observational, and nationwide population-based cohort study of patients with non-traumatic cardiac arrest was designed to investigate the impact of amiodarone and lidocaine usage on survival outcomes. Subjects were selected entirely from the NHIRD, all undergoing DC shock and cardiopulmonary resuscitation during short emergency room stay between January, 2004 and December, 2011. Grounds for exclusion were stipulated as follows: 1) age < 18 years, 2) trauma-related event, 3) emergency room stay > 6 h, or 4) non-level one triage. Patients were categorized and triaged into level-one if vital signs were extremely unstable and needed immediate resuscitation when presented to emergency department. Any known recipients of lidocaine or amiodarone (oral or intravenous) within 1 year previously were also excluded to minimize therapeutic interference. Patients were followed from cardiac arrest index date to 1-year survival status or death. Analysis was based on data from emergency rooms and hospitalization and not from ambulance or from resuscitation on the scene in the study [1].

Acknowledgments

Acknowledgments: This study was supported by National Taiwan University Hospital, Taiwan (Grant number: 102TNY04).

Transparency document. Supplementary material

Transparency data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.dib.2016.11.085.

References

[1] C.H. Huang, P.H. Yu, M.S. Tsai, et al., Acute hospital administration of amiodarone, lidocaine or neither in patients presenting with out-of-hospital cardiac arrest: a nationwide cohort study in press, Int. J. Cardiol. (2016), http://dx.doi.org/10.1016/j.ijcard.2016.11.101, in press.
[2] S.H. Cheng, T.L. Chiang, The effect of universal health insurance on health care utilization in Taiwan. Results from a natural experiment, JAMA 278 (1997) 89–93.
[3] C.J. Shih, H. Chu, P.W. Chao, et al., Long-term clinical outcome of major adverse cardiac events in survivors of infective endocarditis: a nationwide population-based study, Circulation 130 (2014) 1684–1691.